Primary amoebic meningoencephalitis is a rare but fatal central nervous system (CNS) disease caused by the "brain-eating amoeba" Naegleria fowleri. A major obstacle is the requirement for drugs with the ability to cross the blood-brain barrier, which are used in extremely high doses, cause severe side effects, and are usually ineffective. We discovered that the 4-aminomethylphenoxy-benzoxaborole AN3057 exhibits nanomolar potency against N. fowleri, and experimental treatment of infected mice significantly prolonged survival and demonstrated a 28% relapse-free cure rate.

Department of Parasitology Faculty of Science Charles University BIOCEV Vestec Czech Republic

Institute of Biotechnology Czech Academy of Sciences BIOCEV Vestec Czech Republic

Zobrazit více v PubMed

Maciver SK, Piñero JE, Lorenzo-Morales J. 2020. Is PubMed DOI

Cope JR, Ali IK. 2016. Primary amebic meningoencephalitis: what have we learned in the last five years? Curr Infect Dis Rep 18:31. 10.1007/s11908-016-0539-4. PubMed DOI PMC

Grace E, Asbill S, Virga K. 2015. PubMed DOI PMC

Jarolim KL, McCosh JK, Howard MJ, John DT. 2000. A light microscopy study of the migration of PubMed DOI

Yoder JS, Eddy BA, Visvesvara GS, Capewell L, Beach MJ. 2010. The epidemiology of primary amoebic meningoencephalitis in the USA, 1962–2008. Epidemiol Infect 138:968–975. 10.1017/S0950268809991014. PubMed DOI

Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. 2015. Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. J Pediatric Infect Dis Soc 4:e68–e75. 10.1093/jpids/piu103. PubMed DOI

Sood A, Chauhan S, Chandel L, Jaryal SC. 2014. Prompt diagnosis and extraordinary survival from PubMed DOI

Sharma A, Sharma A, Guleria S. 2015. Successful treatment of a case of primary amoebic meningoencephalitis: how important is history taking. Indian J Crit Care Med 19:126–127. 10.4103/0972-5229.151024. PubMed DOI PMC

Dunn AL, Reed T, Stewart C, Levy RA. 2016. PubMed DOI

Heggie TW, Küpper T. 2017. Surviving PubMed DOI

Linam WM, Ahmed M, Cope JR, Chu C, Visvesvara GS, da Silva AJ, Qvarnstrom Y, Green J. 2015. Successful treatment of an adolescent with PubMed DOI PMC

Gharpure R, Bliton J, Goodman A, Ali IKM, Yoder J, Cope JR. 2021. Epidemiology and clinical characteristics of primary amebic meningoencephalitis caused by PubMed DOI PMC

Ali M, Jamal SB, Farhat SM. 2020. PubMed DOI

CDC. 2022.

Siddiqi AK, Chachar MA. 2022. Waters of death: PubMed DOI

Mungroo MR, Khan NA, Siddiqui R. 2019. DOI

Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang Y-K, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MRK. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759–1761. 10.1126/science.1142189. PubMed DOI

Akama T, Baker SJ, Zhang Y-K, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. 2009. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19:2129–2132. 10.1016/j.bmcl.2009.03.007. PubMed DOI

Palencia A, Liu R-J, Lukarska M, Gut J, Bougdour A, Touquet B, Wang E-D, Li X, Alley MRK, Freund YR, Rosenthal PJ, Hakimi M-A, Cusack S. 2016. PubMed DOI PMC

Lunde CS, Stebbins EE, Jumani RS, Hasan MM, Miller P, Barlow J, Freund YR, Berry P, Stefanakis R, Gut J, Rosenthal PJ, Love MS, McNamara CW, Easom E, Plattner JJ, Jacobs RT, Huston CD. 2019. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nat Commun 10:2816. 10.1038/s41467-019-10687-y. PubMed DOI PMC

Zhang Y-K, Plattner JJ, Easom EE, Jacobs RT, Guo D, Freund YR, Berry P, Ciaravino V, Erve JCL, Rosenthal PJ, Campo B, Gamo F-J, Sanz LM, Cao J. 2017. Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate. J Med Chem 60:5889–5908. 10.1021/acs.jmedchem.7b00621. PubMed DOI

Drugs for Neglected Diseases Initiative. 2022. Visceral leishmaniasis: DNDI-6148. https://dndi.org/research-development/portfolio/dndi-6148/. Accessed 8 November 2022.

Drugs for Neglected Diseases Initiative. 2022. Sleeping sickness: acoziborole. https://dndi.org/research-development/portfolio/acoziborole/. Accessed 8 November 2022.

Zhang N, Zoltner M, Leung K-F, Scullion P, Hutchinson S, Del Pino RC, Vincent IM, Zhang Y-K, Freund YR, Alley MRK, Jacobs RT, Read KD, Barrett MP, Horn D, Field MC. 2018. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathog 14:e1006850. 10.1371/journal.ppat.1006850. PubMed DOI PMC

Arbon D, Ženíšková K, Mach J, Grechnikova M, Malych R, Talacko P, Sutak R. 2020. Adaptive iron utilization compensates for the lack of an inducible uptake system in PubMed DOI PMC

Grechnikova M, Ženíšková K, Malych R, Mach J, Sutak R. 2020. Copper detoxification machinery of the brain-eating amoeba PubMed DOI PMC

Ženíšková K, Grechnikova M, Sutak R. 2022. Copper metabolism in PubMed DOI PMC

Baker SJ, Zhang Y-K, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MRK, Sanders V, Plattner JJ. 2006. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 49:4447–4450. 10.1021/jm0603724. PubMed DOI

Zhang H, Cheng X. 2021. Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease. Front Med 15:842–866. 10.1007/s11684-021-0865-2. PubMed DOI

Colon BL, Rice CA, Guy RK, Kyle DE. 2019. Phenotypic screens reveal posaconazole as a rapidly acting amebicidal combination partner for treatment of primary amoebic meningoencephalitis. J Infect Dis 219:1095–1103. 10.1093/infdis/jiy622. PubMed DOI PMC

Escrig JI, Hahn HJ, Debnath A. 2020. Activity of auranofin against multiple genotypes of PubMed DOI PMC